Incara Bextra
Executive Summary
Phase III Beta-blocker Evaluation of Survival trial of the non-selective beta-blocker bucindolol halted due to the absence of statistically significant survival advantage in congestive heart failure patients, Incara (formerly Intercardia), a majority-owned subsidiary of Interneuron, announces July 29